Anti-HMGCR antibodies in systemic sclerosis

The objective of this study was to investigate the frequency of autoantibodies to hydroxymethylglutaryl coenzyme A reductase (HMGCR) in systemic sclerosis (SSc) and associations with inflammatory myositis and statin exposure.This was a cross-sectional, multicenter study of 306 subjects from the Cana...

Full description

Saved in:
Bibliographic Details
Published inMedicine (Baltimore) Vol. 95; no. 44; p. e5280
Main Authors Hudson, Marie, Luck, Yael, Stephenson, Mathew, Choi, May Y., Wang, Mianbo, Baron, Murray, Fritzler, Marvin J.
Format Journal Article
LanguageEnglish
Published United States The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved 01.11.2016
Wolters Kluwer Health
Subjects
Online AccessGet full text
ISSN0025-7974
1536-5964
1536-5964
DOI10.1097/MD.0000000000005280

Cover

More Information
Summary:The objective of this study was to investigate the frequency of autoantibodies to hydroxymethylglutaryl coenzyme A reductase (HMGCR) in systemic sclerosis (SSc) and associations with inflammatory myositis and statin exposure.This was a cross-sectional, multicenter study of 306 subjects from the Canadian Scleroderma Research Group cohort who had complete data on statin exposure and serology for anti-HMGCR antibodies assayed by an addressable laser bead immunoassay (ALBIA). Descriptive statistics were used to summarize the baseline characteristics of the patients and to compare subjects with and without anti-HMGCR antibodies.Four (1.3%) subjects had anti-HMGCR antibodies. None of the subjects with anti-HMGCR antibodies titers had a history of an inflammatory myositis or overlap with polymyositis/dermatomyositis, compared to 8.6% and 2.0% of those without anti-HMGCR antibodies, respectively. In addition, none of the subjects with anti-HMGCR antibodies had past or current exposure to statins compared to 12% of those with negative titers.Anti-HMGCR antibodies are rare in SSc and are not associated with inflammatory myopathy or statin exposure. Larger studies will be required to confirm these preliminary observations. Nevertheless, we conclude that anti-HMGCR antibodies are unlikely to play a major role in inflammatory myopathy in SSc and anti-HMGCR antibodies can be present in subjects without exposure to statins.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0025-7974
1536-5964
1536-5964
DOI:10.1097/MD.0000000000005280